Receptors of peptides as therapeutic targets in epilepsy research by Dobolyi, A. et al.
Send Orders for Reprints to reprints@benthamscience.net 
 Current Medicinal Chemistry, 2014, 21, 1-24 1 
 0929-8673/14 $58.00+.00 © 2014 Bentham Science Publishers 
Neuropeptides in Epilepsy 
A. Dobolyi*,1, K.A. Kékesi2,3, G. Juhász2, A.D. Székely4, G. Lovas5,6 and Z. Kovács7 
1
Laboratory of Molecular and Systems Neuroscience, Institute of Biology, Eotvos and the Hungarian Academy of Sci-
ences, H-1094 Budapest, Hungary; 
2
Laboratory of Proteomics, Institute of Biology, Eötvös Loránd University, H-1117 
Budapest, Hungary; 
3
Department of Physiology and Neurobiology, Eötvös Loránd University, H-1117 Budapest, Hun-
gary; 
4
Department of Anatomy, Histology and Embryology, Semmelweis University, H-1094 Budapest, Hungary; 
5
Department of Neurology, Semmelweis University, Budapest, H-1083, Hungary; 
6
Department of Neurology, Jahn Fer-
enc Teaching Hospital, Budapest, H-1204, Hungary; 
7
Department of Zoology, University of West Hungary, Savaria 
Campus, H-9700, Szombathely, Hungary 
Abstract: Neuropeptides are signaling molecules participating in the modulation of synaptic transmission. Neuropeptides 
are stored in dense core synaptic vesicles, the release of which requires profound excitation. Only in the extracellular 
space, neuropeptides act on G-protein coupled receptors to exert a relatively slow action both pre- and postsynaptically. 
Consequently, neuropeptide modulators are ideal candidates to influence epileptic tissue overexcited during seizures. In-
deed, a number of neuropeptides have been implicated in epilepsy and many of them are considered to have endogenous 
neuroprotective actions. Neuropeptides, present in the hippocampus, the most frequent focus of seizures in temporal lobe 
epilepsy, received the largest attention as potential anti-epileptic substances. Hippocampal neuropeptides, somatostatin, 
neuropeptide Y, galanin, dynorphin, enkephalin, substance P, cholecystokinin, vasoactive intestinal polypeptide, and some 
neuropeptides, which are also hormones such as ghrelin, angiotensins, corticotropin-releasing hormone, adrenocorticotro-
pin, thyrotropin-releasing hormone, oxytocin and vasopressin involved in epilepsy are discussed in the review article. Oral 
application of neuropeptides as drugs is typically not efficient because of low bioavailability: rapid degradation and insuf-
ficient penetration through the blood-brain barrier. Recent progress in the development of non-peptide agonists and an-
tagonists of neuropeptide receptors as well as gene therapeutic approaches leading to the local production of neuropep-
tides within the central nervous system will also be discussed. 
Keywords: Neuromodulation, neuronal plasticity, neuropeptide receptors, seizure, temporal lobe epilepsy, therapeutic applica-
tion. 
1. INTRODUCTION 
Epilepsy is a group of disorders characterized by sei-
zures, excessive neuronal activity in the brain. Epilepsy af-
fects 4-6 of out 10000 individuals each year. Approximately 
50 million people are affected worldwide according to a re-
port by World Health Organization (www.who.int/medi-
acentre/factsheets/fs999/en/). A number of drugs are avail-
able for the treatment of patients suffering from the different 
types of epilepsies. However, about 30-35% of patients do 
not properly respond to any drugs and continue to have sei-
zures with a frequency that seriously hinders working ability, 
and reduces intellectual capabilities and life quality [1]. 
All forms of epilepsy result from shifting the excita-
tory/inhibitory balance of nerve cells toward excitation caus-
ing hyperexcitability, which can spread in the central nerv-
ous system. Increasing the inhibitory tone or decreasing the 
excitatory tone is the purpose of medications [2]. Most of the 
current medications achieve this goal by inhibiting ion chan-
nels or glutamatergic neurotransmission, or alternatively 
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promote GABA-ergic neurotransmission [3]. The fast trans-
mitters as Glu and GABA are major factors in epileptic sei-
zure genesis but all drugs targeting their receptors also influ-
ence an immense number of other cells, which results in a 
significant spectrum of side-effects [4]. Because the recep-
tors and ion channels in neurons have a complex interacting 
network of membrane proteins linking the external influ-
ences to intracellular signaling systems and alterations in 
gene transcription, theoretically, the epileptic cells can be 
controlled by many different ways. Optimal fine tuning of 
excitatory-inhibitory balance of neurons cannot be achieved 
by drugs acting on GABA or Glu receptors as even physio-
logically, these roles are achieved by co-transmitters and 
modulators. Neuromodulator substances do not transmit fast 
information in synapses but rather modulate the efficacy of 
neurotransmission directly or indirectly using various signal 
transduction mechanisms [5]. Indeed, different neuromodula-
tory systems including neuropeptides, nitric-oxide, nucleo-
sides, steroids, cytokines, growth factors, cannabinoids have 
been suggested to affect the formation and propagation of 
seizures and, therefore, might represent target candidates for 
drug development [6]. The present review focuses on neu-
ropeptides and we tried to make a collection of information 
useful for drug discovery and for understanding epilepsy at 
neurochemical level. 
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2. NEUROPEPTIDES 
Neuropeptides consist of 3-50 amino acids (aa) encoded 
by the genome. Thus, some peptides, synthesized enzymati-
cally such as glutathione or aspartyl-glutamate, do not be-
long to neuropeptides. Neuropeptides are always cleaved 
enzymatically by prehormone convertases in the endoplas-
mic reticulum and the Golgi apparatus, and often undergo 
additional posttranslational modifications such as amidation, 
pyroglutamate formation, etc. [7]. Neuropeptides are then 
packed into so-called dense core vesicles and transported to 
the presynaptic terminals [8]. Importantly, these vesicles are 
not released by single action potentials or low-frequency 
stimulation even though small vesicles containing neuro-
transmitters are released by this stimulus at the same synapse 
[9]. Thus, neuropeptides typically have no effect on the basal 
function of the network [10]. In turn, high-frequency stimu-
lation leads to the secretion of a large amount of neuropep-
tides, which can act locally or more distantly by diffusion. 
Neuropeptides always act via high-affinity G-protein cou-
pled receptors [11]. There is not a single neuropeptide the 
receptor of which is a ligand-gated ion channel in verte-
brates. Some proteins considered neuropeptides by some 
researchers, e.g. prolactin and leptin, have single transmem-
brane domain tyrosine-kinase receptors. However, it is more 
logical to not consider these signal proteins as neuropeptides. 
Thus, all neuropeptides possess 7 transmembrane domain 
receptors, which belong to 2 subgroups [12]. Typically, the 
receptors of small neuropeptides (3-30 aa) are class I, 
rhodopsin-like G-protein coupled receptors while larger neu-
ropeptides (25-50 aa) possess class II, secretin-like G-
proteins coupled receptors [13]. Neuropeptides are elimi-
nated from the extracellular space by proteolytic degrada-
tion. After neuropeptides are released from the presynaptic 
terminal, they are not taken back by the terminals and the 
large dense core vesicles cannot be replenished [8]. Instead, 
newly synthesized neuropeptide packages arrive from the 
cell body, a process, which takes a significant amount of 
time, several hours or even days [14]. These properties of 
neuropeptides have to be taken into account when assessing 
their role during and after seizures. The high frequency dis-
charge of neurons participating in the development and 
propagation of seizures leads to the release of neuropeptides 
[15]. On the other hand, neuropeptides are not available after 
being depleted, which may contribute to the maintenance of 
epileptic seizures, and the rearrangement and stabilization of 
the epileptic focus [16].  
3. NEUROPEPTIDE SYSTEMS AS DRUG TARGETS 
There are over 100 different neuropeptides identified so 
far in the human brain. They often have highly circum-
scribed localization restricted to a few cell types. Even the 
distribution of the most widespread neuropeptides is consid-
erably more restricted than that of fast neurotransmitter sys-
tems. Thus, we can claim that drugs acting on neuropeptide 
receptors have the potential for small side-effects not only 
because of the lack of interference with the basal function of 
the network but also because of restricted localization of 
their receptors. On the other hand, there are some inherent 
difficulties in drug development in the neuropeptide field. 
Namely, neuropeptides are metabolized in the gastrointesti-
nal system, have a short half-life in the circulation because of 
endogenous plasma protease activity, and typically do not 
cross the blood-brain barrier [17]. Still, there are a number of 
clinical trials to investigate the presence of neuropeptides as 
biomarkers (e.g. in migraine, pain, Parkinson’s disease, ma-
ternal obesity, behavioral and mood disorders) or their poten-
tial therapeutic effects (e.g. in mood disorders, autism, pain). 
To increase the bioavailability of neuropeptides for better 
utilization of their therapeutic potentials, non-peptide ago-
nists and antagonists are needed, which often represents a 
difficult task as the binding site of the receptor is suited to 
accept the larger peptide as ligand. Nevertheless, some pro-
gress has been made in this field and small molecule ligands 
have been developed for some neuropeptide receptors as 
discussed below [18]. Furthermore, the fact that neuropep-
tides are genetically coded can be utilized by gene transfer 
methods [19]. Indeed, constitutive or even regulated expres-
sion of a number of neuropeptides has been tested in recent 
years in clinical trials [20]. Engineering artificial neuropep-
tides is also relatively straightforward. In particular, chang-
ing a handful of the amino acids within neuropeptides can 
result in increased receptor specificity, or the opposite: an-
tagonists can be generated this way [21]. The introduction of 
these artificial agonists and antagonists is also possible by 
gene transfer tools [22]. Using viral tools, the expression of 
neuropeptide agonists and antagonists can be restricted either 
by local injections or by using molecular biological tech-
niques for the infection and action in specific cell types. Re-
cent progress in this field will be discussed for neuropeptides 
tested to be delivered by gene transfer. 
4. NEUROPEPTIDE SYSTEMS INVOLVED IN EPI-
LEPSY 
Epilepsies can be divided on a phenomenological basis 
into two major categories: generalized and partial epilepsies 
depending on whether both hemispheres of the brain is in-
volved with a loss of consciousness or only circumscribed 
brain regions are affected during the seizure. One of the most 
common epileptic focuses in partial epilepsies is the tempo-
ral lobe, particularly the hippocampus. Therefore, no wonder 
that neuropeptides present in the hippocampus received the 
largest attention in epilepsy research. In addition, it is a key 
clinical observation that a relatively high percentage of pa-
tients with temporal lobe epilepsy do not respond to even 
combined medication (therapy refracter epilepsy, where the 
complete or partial surgical removal of the affected lobe 
might be necessary) warranting the need for novel ap-
proaches. The hippocampus proper (the dentate gyrus and 
the Ammon´s horn) receives its major input from another 
part of the hippocampal formation, the enthorhinal cortex 
(the perforant pathway to the dentate gyrus), and provides its 
major output to the subiculum, through which the hippocam-
pus proper is connected with other cortical areas. Additional 
subcortical connections of the hippocampus include the 
amygdala, the septum, the thalamic reuniens nucleus, and the 
mamillary region of the hypothalamus. Several neuropep-
tides are located in the intrinsic neurons of the hippocampus 
proper supplementing glutamate in excitatory projection neu-
rons and GABA in inhibitory interneurons. The projection 
neuron of the dentate gyrus is the granule cell, which con-
tains dynorphin. The other 2 layers of the dentate gyrus, the 
molecular layer and the hilus also contain different neu-
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ropeptides. The pyramidal cells in the pyramidal layer of the 
CA1-CA3 regions of the hippocampus do not contain neu-
ropeptides under normal circumstances, but some neuropep-
tides could be induced in them by seizures. In turn, a number 
of different types of interneurons have been identified with 
diverse neuropeptide content in other layers of the hippo-
campus, including the stratum oriens, the stratum radiatum, 
and the stratum lacunosum/molecular [23]. Somatostatin, 
neuropeptide Y, galanin, opioids, substance P, cholecystoki-
nin, and vasoactive intestinal polypeptide are the best known 
neuropeptides present in the hippocampus [24]. The Am-
mon´s horn and the CA1 region in particular, are most af-
fected histopathologically in patients with temporal lobe 
epilepsy. Degeneration of this region known as hippocampal 
sclerosis is often evident in the pyramidal cell layers. Reor-
ganization of interneurons is characteristic of epilepsy histo-
pathology in both the dentate gyrus and the Ammon´s horn 
[25], which is accompanied by changes in neuropeptide ex-
pression and function. Hippocampal neuropeptides, their 
distribution, involvement in seizures, receptors, as well as 
their current status in anti-epileptic drug development will be 
the subject of the current review. 
In addition to focal epilepsies, neuropeptides might also 
be involved in generalized epilepsies, e.g. absence epilepsy. 
In absence epilepsy, the seizures are based on activation of 
T-type Ca2+ channels [26], which open at slightly hyperpo-
larized membrane potential. The sustained hyperpolarization 
is probably the result of an increase in GABAergic tone. 
Absence seizures are generated in the thalamo-cortical cir-
cuits and involve thalamic relay neurons, GABAergic neu-
rons of the reticular thalamic nucleus, cortical pyramidal 
cells and interneurons. In principle, all neuropeptides present 
in the thalamo-cortical absence seizure genesis loop are po-
tential participants of absence epilepsy mechanism. For ex-
ample, neuropeptide Y was suggested as a putative anti-
epileptic peptide in the thalamo-cortical loop and suppressed 
absence seizures [27, 28]. Several other neuropeptides are 
also involved in the generation and maintenance of seizures, 
and therefore, their receptors represent potential drug targets. 
These neuropeptides, -many of them having additional hor-
monal functions, too, such as ghrelin, angiotensins, cortico-
tropin-releasing hormone, adrenocorticotropin, thyrotropin-
releasing hormone, oxytocin, and vasopressin-, will also be 
discussed in the paper. 
5. SPECIFIC NEUROPEPTIDE SYSTEMS AS PO-
TENTIAL DRUG TARGETS IN EPILEPSY 
5.1. Somatostatin 
The 28 aa somatostatin is produced in the digestive sys-
tem, the stomach, the intestine and the delta cells of the pan-
creas whereas the 14 aa somatostatin is dominant in the brain 
[29]. Here, somatostatin has a relatively widespread distribu-
tion including the periventricular hypothalamic nucleus in-
hibiting growth hormone secretion. Its expression level is 
also remarkably high in the cerebral cortex [30]. In the hip-
pocampus, somatostatin is produced in a variety of inhibitory 
neurons including hilar interneurons, bistratified cells, and 
O-LM interneurons in the Ammon´s horn [24]. Somatostatin 
cells in the hilus make up to 16% of total inhibitory interneu-
rons in the dentate gyrus [31]. The terminals of these cells 
are in the outer molecular layer and presumably affect per-
forant path excitatory synapses [32]. Bistratified cells have 
axon terminals in both the stratum oriens and radiatum and 
may reduce the excitatory influence of Schaffer collaterals 
on the dendrites of pyramidal cells [33]. The cell bodies and 
horizontal dendrites of O-LM cells are located in the stratum 
oriens and provide inhibition to the distal dendrites of py-
ramidal cells in the stratum lacunosum-moleculare [34]. So-
matostatin is released from hippocampal neurons after sei-
zures [35] and its expression was enhanced by seizures in 
animal models [36]. However, a loss of somatostatin in-
terneurons was found in the hilus in human temporal lobe 
epilepsy and in animal models of epilepsy while soma-
tostatin usually remained in the Ammon´s horn even in scle-
rotic hippocampus [37, 38]. From these data, as well as a 
number of animal experiments on the effect of seizure activ-
ity of somatostatin, it was concluded that somatostatin has 
neuroprotective function and anti-epileptic action [39]. In-
deed, somatostatin inhibits spontaneous and evoked epilepti-
form bursting in vitro [40] while reducing glutamate release 
in the hippocampus [41]. Somatostatin, injected intracere-
broventricularly [42] or overexpressed in the hippocampus 
using viral tools [43] decreased the severity of seizures in 
vivo. In turn, sequestering endogenous somatostatin by infu-
sion of an anti-somatostatin antibody had pro-convulsant 
effects [44]. 
Somatostatin can act on 5 different somatostatin recep-
tors (sst1-sst5), which are all coupled to Gi/o, and of which 
sst1-sst4 are expressed in the hippocampus [45]. Sst1 recep-
tors are often autoreceptors and probably do not participate 
in the action of somatostatin on epileptic activity [46, 47]. 
Sst2-sst4 receptors are located in granule cells of the dentate 
gyrus and in pyramidal cells of the Ammon´s horn [45]. Re-
cently, some somatostatin receptor subtype-selective small 
molecule drugs were developed using combinatorial libraries 
constructed on the basis of molecular modeling of known 
peptide agonists [48]. These studies relied on using sugar or 
benzodiazepinone non-peptide mimics of betaII´ turn around 
the biologically essential Trp-Lys dipeptide at the 8 and 9 
position of somatostatin. In subsequent studies, these ago-
nists (Fig. 1) have also been characterized in vivo [49]. Later, 
selective antagonists of sst1 [50], sst2 [51], and sst3 [52] were 
also developed, which can be useful experimental tools, al-
though the latter two are peptide derivatives. 
Sst2-sst4 all participate in the mediation of the anti-
convulsant action of somatostatin although with some spe-
cies-dependence regarding sst2 in particular, which appears 
to have an anti-epileptic action in rats but not in mice [53]. 
The selective sst2 agonist L-779,976, the sst3 agonist L-
796,778, and the sst4 agonist L-803,087 all protected rats 
against focal pilocarpine-induced seizures [54]. Apart from 
pharmacological tools, transgenic animals lacking soma-
tostatin receptors also suggest the role of these receptor sub-
types in epilepsy [46]. Despite the extensive results of ani-
mal experimentation available, however, human data are 
largely missing as far as the anti-epileptic activity of soma-
tostatin. Therefore, further progress in this field is eagerly 
awaited. 
5.2. Neuropeptide Y 
Neuropeptide Y (NPY) is a 36 aa neuropeptide expressed 
in the nervous system and in a variety of secretory cells in 
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the periphery. Within the central nervous system, NPY is 
most abundant in the cerebral cortex, the hippocampus, the 
hypothalamus, the striatum and the reticular nucleus of the 
thalamus [55]. Within the hippocampus, NPY is expressed in 
bistratified GABA-ergic interneurons [23] and inhibits the 
excitatory input onto pyramidal cells in the Ammon´s horn 
[56]. NPY levels are increased in epilepsy models [57] but 
prolonged overstimulation in animal models or in human 
epilepsy ablates NPY [38, 58]. Additional evidence for the 
involvement of NPY in epilepsy was provided by the finding 
that valproate, a widely used anti-epileptic drug elevated 
NPY levels in the hippocampus [59].  
A large body of information provided evidence that ex-
ogenously applied NPY has anti-epileptic activity in both in 
vitro models (bursting without Mg2+, picrotoxin and stimu-
lus-train induced bursting in hippocampal slices), and in vivo 
models of partial seizures such as different kindling models 
and kainate-induced seizures reviewed previously [60, 61]. 
Although less extensively studied, NPY may also be benefi-
cial in models of generalized seizures, the pentylenetetrazole 
[62] and the electroconvulsive seizures [63], and models of 
absence epilepsy [28]. Studies using transgenic animals also 
suggest a role of NPY in the control of seizures. In mice 
lacking a functional NPY gene, spontaneous seizures were 
observed and their threshold for pentylenetetrazole was re-
duced [64]. In turn, rats overexpressing NPY showed dimin-
ished kainate and kindling-induced seizures [65]. Gene trans-
fer studies in the field of epilepsy are also pioneered using 
the neuropeptide Y system. Overexpression of NPY in the 
hippocampus using adeno-associated viral vectors sup-
pressed the consequences of kainate- and kindling-induced 
seizures [66]. A similar gene transfer method reduced spon-
taneous seizure frequency in a progressive and spontaneous 
seizure model of temporal lobe epilepsy induced by electri-
cal stimulation of the temporal pole of the hippocampus [67]. 
At present, however, neuropeptide Y is used in clinical trials 
of a number of disorders like mood disorders, post traumatic 
stress disorder but not in epilepsy [68]. 
There are 4 different neuropeptide receptors identified in 
human, Y1, Y2, Y4 and Y5, of which Y1, Y2 and Y5 may 
be involved in epilepsy [61]. These receptors signal through 
Gi proteins that inhibit adenylate cyclase and decrease intra-
cellular Ca2+ levels [69]. Y2 has predominantly presynaptic 
localization while Y1 and Y5 reside on postsynaptic neurons 
[70] possibly with different excitatory or inhibitory nature. 
Y1 receptor overexpression aggravated kainate-induced sei-
zures [71] while Y5 receptor overexpression together with 
NPY overexpression had stronger seizure-suppressant effect 
than NPY overexpression alone [72]. In addition, mice lack-
ing the Y5 receptor had enhanced sensitivity for kainate-
induced seizures [73]. Experiments with Y2 knockout mice 
and overexpression of the selective Y2 ligand NPY13-36 
suggest that Y2 receptor is also involved in the suppression 
of seizures [74, 75]. In line with these studies, Y1 antago-
nists, and Y2 and Y5 agonists were suggested to have anti-
epileptic potential [76]. Indeed, a large number of different 
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Fig. (1). Non-peptide agonists acting selectively on sst1-sst4 receptors. 
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peptide derivatives of NPY were tested in animal models of 
epilepsy supporting this suggestion [60]. However, the de-
velopment of selective drugs acting on NPY receptors lags 
behind the understanding of their importance. Some non-
peptide Y1 antagonists are available and a selective peptide-
derivative Y5 agonist (BWX-46; ((CYS31,NVA34)-
Neuropeptide Y (27-36))2) has been reported [77] while se-
lective small molecule Y2 agonists are not available yet. The 
selective Y1 receptor antagonists BIBP 3225 and BIBO 3304 
decreased seizure susceptibility in rats [62]. Another Y1 re-
ceptor antagonist, BIBP-3226 (Fig. 2A) was also investi-
gated in structure-activity studies. Replacing the benzy-
lamino by a tetrahydrobenzazepinyl group preserves most of 
the Y1 activity while combination with a NG-phenylpropyl 
arginine and a Na-p-biphenylylacetyl moiety shifted the 
NPY receptor selectivity towards Y5 [78]. Using BIBO-3226 
as a lead compound resulted in some other Y1 antagonist but 
these ligands were not superior to the parent compound [79, 
80]. 
5.3. Galanin 
Galanin consists of 29 amino acids in rodents and 30 
amino acids in human. It is expressed in the gastrointestinal 
tract, and the nervous system. In the central nervous system, 
galanin is abundant in the hypothalamus, the cortex, the hip-
pocampus, and the brainstem. Galanin-immunoreactive 
nerve terminals have a particularly high density in the gran-
ule cell layer of the dentate gyrus. Some of these terminals 
originate in the septum and also contain acetylcholine [81]. 
Other galanin-containing terminals in the dentate gyrus are 
catecholaminergic and arise from the locus coeruleus [82]. In 
addition, seizures lead to the expression of galanin in hippo-
campal inhibitory neurons [83, 84]. Furthermore, galanin 
receptors were identified on serotonergic raphe neurons pro-
jecting to the hippocampus [85]. Thus, galanin was sug-
gested to also influence limbic seizures indirectly via these 
brainstem galanin receptors [86]. 
Galanin leads to the inhibition of glutamate release in the 
hippocampus [87], which probably is the reason of the anti-
seizure effect of intrahippocampal galanin injection [88]. 
The anti-convulsant activity of galanin was also supported 
using transgenic mice lacking galanin as these mice demon-
strated an increased seizure susceptibility and higher severity 
of convulsions [89]. In turn, mice overexpressing galanin 
showed an increased discharge threshold and a reduced pro-
gression of kindled seizures [90]. Similarly, viral overex-
pression of galanin also suppressed seizure development [91, 
92]. 
There exist 3 subtypes of galanin receptors (GalR) in 
mammals. These receptors are inhibitory G-protein coupled 
receptors. Two of them, GalR1 and GalR2 are expressed in 
the hippocampus [93]. Mice lacking GalR1 showed sponta-
neous seizures and were highly sensitive in induced epilepsy 
models [94]. Timing of the effects of antisense DNA for 
GalR2 suggested that GalR1 affects the initiation phase 
while GalR2 affects the maintenance phase of status epilep-
ticus [95]. Selective chimeric peptides for the GalR1 (M617: 
Galanin(1-13)-Gln14-bradykinin(2-9)amide) and for GalR2 
(M1145: (RG)(2)-N-galanin(2-13)-VL-(P)(3)-(AL)(2)-A-
amide) were developed [96, 97]. To produce GalR agonists 
with increased stability and blood-brain barrier penetration 
capability, truncated galanin analogues, in which nonessen-
tial amino acid residues were replaced by cationic and/or 
lipoamino acid residues, were designed. That way, a non-
selective GalR1-GalR2 peptide NAX 5055 was produced, 
which contains the -Lys-Lys-Lys(palmitoyl)-Lys-NH(2) mo-
tif and exhibited high affinity for galanin receptors. Struc-
ture-activity-relationship analysis suggested that cationiza-
tion combined with position-specific lipidization was critical 
for improving the systemic activity of the analogues [98]. 
These, and some other peptides with various degrees of 
galanin receptor selectivity, had anti-convulsant properties in 
a variety of epilepsy models suggesting the involvement of 
both GalR1 and GalR2 in epilepsy [86]. Therefore, the de-
velopment of small molecule agonists on galanin receptors 
became a goal of many pharmaceutical companies. Instead 
of true agonists, however, some positive allosteric modula-
tors were developed. Galmic (Fig. 2B) and galnon (Fig. 2C) 
bind to both GalR1 and GalR2 with similar and unfortu-
nately low affinities [99-101]. Still, both substances possess 
the advantage of allosteric modulators: they activate the re-
ceptor only in the presence of the endogenous agonist, that 
is, when the receptor is supposed to be activated thereby 
reducing the side-effects resulting from non-physiological 
activity of the receptor [102]. More recently, a modified ver-
sion of galnon, CYM2503 (Fig. 2D) was produced as a high 
affinity allosteric modulator [103], the utilization of which is 
promising in future research on the anti-convulsant action of 
galanin receptors [104]. 
5.4. Dynorphin and Enkephalin 
Dynorphins and enkephalins are opioid peptides, that is, 
endogenous ligands of the opiate receptors, through which 
morphine exerts its anti-nociceptive actions [105]. Dynor-
phin A and B are both 13 aa peptides encoded by the prepro-
dynorphin gene. They act on the kappa-opioid receptors 
(KOR). Enkephalins also have 2 forms, met-, and leu-
enkephalin, which are both 5 aa peptides differing in one 
amino acid. They act on the mu- and delta-opioid receptors 
(MOR and DOR). Met-enkephalin peptide sequence is coded 
for by the preproenkephalin gene; the leu-enkephalin peptide 
sequence is coded for by both the preproenkephalin gene and 
the preprodynorphin gene [106]. The third family of opioid 
peptides, the endorphins, has not been significantly impli-
cated in the generation and control of seizures even though 
all opioid peptides are present in several brain regions [107]. 
In the hippocampus, enkephalins are present in mossy fibers, 
the perforant path, and in scattered GABAergic interneurons 
while dynorphins are present in granule cells, as well as per-
forant path and supramammillary afferents [108]. Kindling 
and seizures were shown to increase the release of 
enkephalin [109, 110]. In turn, the expression level and con-
centration of enkephalins are increased during and after sei-
zures. Generalized clonic-tonic seizures increased the pre-
proenkephalin gene expression in the dentate gyrus [111, 
112]. In a spontaneously epileptic strain, a strong upregula-
tion of enkephalin was found in the granule cells and mossy 
fibers [113]. An enhancement of proenkephalin expression 
was found after pentylenetetrazol treatment, too [114]. A 
single dose of kainic acid elevates the levels of enkephalins 
in the hippocampus for up to 1 year [115]. Furthermore, an 
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increase in enkephalin-like immunoreactivity was found in 
human hippocampi with generalized epilepsy [116]. The 
induction of preproenkephalin is also in line with the activa-
tion of enkephalin-synthesizing neurons during seizures 
[117]. In contrast, most studies reported a decreased level of 
dynorphins following seizures. Generalized clonic-tonic sei-
zures decreased the preprodynorphin gene expression in the 
dentate gyrus [111] and the Ammon´s horn [112]. Dynorphin 
mRNA levels were decreased in a spontaneously epileptic 
mouse strain [113]. Status epilepticus induced by intermit-
tent stimulation of the perforant path also decreased the 
dynorphin-like immunoreactivity in the dentate gyrus and 
CA3 [118]. However, an up-regulation of prodynorphin tran-
scription was found in human temporal lobe epilepsy [119]. 
The acute changes in the level of opioid peptides may con-
tribute to increased excitation during induction of seizures, 
while the chronic changes may contribute directly to persis-
tently increased excitability in the hippocampus and possibly 
other brain regions, too [112]. 
Apart from the different alterations in their level during 
seizures, enkephalin and dynorphin had opposite effects in 
their action on seizure susceptibility [120, 121]. DOR ago-
nists produce convulsions similar to the effect of pentyle-
netetrazol [122] while MOR agonists also evoked EEG epi-
leptiform activity [123-125]. Also, MOR agonists intensified 
the neurotoxic effects of kainate in the hippocampus [126]. 
In turn, MOR and DOR antagonists raised seizure threshold 
[127], depressed pentylenetetrazol-induced kindling in rats 
[128, 129], and prevented wet dog shaking and status epilep-
ticus following perforant path stimulation [118, 130]. Elec-
troshock seizure threshold was also increased by MOR an-
tagonists [131]. Bicuculline-induced convulsions were po-
tentiated by intracerebroventricularly administered 
enkephalin derivatives while selective MOR as well as DOR 
antagonists abolished the enhancement of the bicuculline-
induced convulsions [132]. In contrast, selective KOR ago-
nist suppressed bicuculline-induced convulsions [132] and 
showed a marked anti-convulsant profile in different animal 
models of epilepsy [133]. These findings are consistent with 
the neuromodulatory actions of opioid peptides. Enkephalin 
inhibited GABA release from inhibitory interneurons, result-
ing in increased excitability of hippocampal pyramidal cells 
and dentate gyrus granule cells. The role of enkephalins as 
pro-convulsive agents is also consistent with the seizure-
inducing side-effect of high concentration morphine treat-
ment [134, 135]. Prodynorphin-derived peptides primarily 
acted at presynaptic kappa opioid receptors to inhibit excita-
tory amino acid release from perforant path and mossy fiber 
terminals [108, 136]. Furthermore, direct injection of a DOR 
receptor antagonists or dynorphin-A into the hilus of the 
dentate gyrus prevented the development of status epilepti-
cus by perforant path stimulation while perihilar administra-
tion of a DOR agonist enkephalin derivative or a kappa-
antagonist facilitated the establishment of self-sustaining 
status epilepticus suggesting actions in the hippocampus 
[118]. Altogether, these data suggest that kappa-opioids in 
the hippocampus counteract but delta-opioids promote initia-
tion and maintenance of status epilepticus. In addition to 
limbic seizures, dynorphin may also suppress encephalitis-
induced seizures [137, 138] and absence eplileptic-like sei-
zures [139] suggesting that its anti-convulsive action is not 
restricted to specific epilepsies connected to the hippocam-
pus. In fact, opioids could have indirect actions on the hip-
pocampus, too, as medial septal injection of the opioid an-
tagonist naloxone elevated acetylcholine release in the hip-
pocampus and induced seizures in the rat [140]. Additional 
strong evidence on the involvement of dynorphin in seizure 
activity came from studies using mice that lack functional 
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prodynorphin gene. These mice displayed a reduced seizure 
threshold in response to pentylenetetrazole. This phenotype 
could be entirely rescued by kappa receptor-specific agonist 
while a delta-specific agonist decreased seizure threshold in 
both wild-type and knockout mice [141]. Moreover pro-
dynorphin knockout mice showed faster seizure onset and a 
prolonged time of seizure activity after kainate injection, 
which was accompanied by an increased extent of neuronal 
loss in the hippocampus [142]. The involvement of dynor-
phin in the etiology of epilepsy was also strengthened by a 
functional polymorphism in the prodynorphin gene promotor 
associated with temporal lobe epilepsy. In a case control 
association study, the prodynorphin promotor low-
expression L-alleles conferred an increased risk for temporal 
lobe epilepsy. Irrespective of the familial background, L-
homozygotes displayed a higher risk for secondarily general-
ized seizures and status epilepticus [143]. 
Primary opioid receptors, MOR, DOR and KOR, and the 
nociceptin/orphanin FQ peptide receptor, have been further 
classified pharmacologically. However, cloning and knock-
out technologies did not support the existence of the pharma-
cologically classified receptor subtypes [144]. Opioid recep-
tors can couple to Gi, Go, Gq, and possible Gz/x. Opioids in-
hibit adenylate cyclase and Ca2+ channels, and stimulate K+ 
channels by Gi and Go, while coupling with Gq leads to the 
activation of phospholipase C [145]. The pharmacology of 
opioid receptors is exceptionally well elaborated. Several 
different KOR agonists are available and used as analgesics 
in clinical practice [146]. Non-peptide, selective KOR ago-
nists include asimadoline, bremazocine, butophanol, BRL-
52537, cyclazocine, enadoline, GR-89696, HZ-2, ICI-
199,441, ketazocin, LPK-26, salvinorin B methoxymethyl 
ether, spiradoline, tifluadom, U-50488, U-69593, which be-
long to different chemical classes of molecules. Some of 
these drugs including asimadoline ICI-204,448 do not cross 
the blood brain barrier, and therefore, are not suitable to test 
as anti-epileptics. Some other compounds including buto-
phanol (Fig. 3A), cyclazocine (Fig. 3B), ketacyclazocine 
(Fig. 3C), salvinorin A (Fig. 3D), and U-50488 (Fig. 3E) 
have been tested in animal models and demonstrated anti-
convulsant properties [147-151]. Other potential anti-
epileptic compounds based on their above described actions 
are MOR and DOR antagonists [152]. Selective non-peptide 
MOR antagonists include cyprodime (Fig. 3F), and beta-
Funaltrexamine (Fig. 3G). Stable peptide analogues, such as 
[Dmt1, d-2-Nal4]endomorphin-2, designated as antanal-2, 
have also been developed. These drugs were tested in epi-
lepsy models and were found to be anti-convulsant [130, 
132, 153-156]. Selective non-peptide DOR antagonists in-
clude naltrindole (Fig. 3H) and naltriben (Fig. 3I), which 
showed anti-convulsant properties in different animal models 
of epilepsy [118, 128, 129, 132]. Therefore, KOR agonists, 
MOR and DOR antagonists should be further investigated as 
anti-epileptics despite potential major side-effects including 
dysphoria. 
5.5. Substance P 
Substance P belongs to the tachykinin family of peptides 
and consists of 11 amino acids [157]. It has a relatively 
widespread distribution in the brain including the hippocam-
pus. Some substance P-expressing neurons are found in the 
subiculum and enthorhinal cortex. The granule cells, and 
some interneurons of the hilus, stratum oriens and stratum 
radiatum of the Ammon's horn also contain substance P 
[158, 159]. However, the substance P-containing fibers 
densely innervating the hippocampal formation [158-160] 
derive to a large extent from extrahippocampal sources, the 
supramammillary nucleus [161] and the medial septum 
[162]. Furthermore, substance P expression within the hip-
pocampus is increased by seizures [113, 163]. 
Substance P plays a role in sustaining status epilepticus 
[16]. In addition, a resistance to excitotoxin-induced seizures 
and neuronal death was found in mice lacking the prepro-
tachykinin A gene, which encodes substance P [164]. Fur-
thermore, the involvement of substance P in other types of 
seizures, e.g. seizures in neurocysticercosis has also been 
firmly established [165]. The mechanisms of the pro-
convulsant effect of substance P are not known yet. Sub-
stance P modulates synaptic transmission [166] and can de-
polarize cortical neurons to elicit an increase in glutamate 
release at excitatory synapses [167]. Substance P typically 
affects interneurons, therefore, a facilitation of inhibitory 
drive to GABA-ergic interneurons may be the mechanism of 
overexcitation of the epileptic tissue [168]. 
Substance P acts relatively specifically on neurokinin-1 
(NK-1) receptor [157]. This receptor can couple to Gq/11, Gs 
and G0 proteins [169]. Stimulation of NK1 receptor activates 
phospholipase C and also adenylate cyclase without cross-
talk between the signaling pathways [170]. Immunostaining 
for substance P receptor labels GABA-ergic interneurons 
with distinct termination patterns in the hippocampus [171, 
172]. The morphology and synaptic input of substance P 
receptor-immunoreactive interneurons alters in epileptic hu-
man hippocampus [173]. Substance P receptor-
immunopositive cells possess significantly larger numbers of 
dendritic branches in the epileptic CA1 region, and the syn-
aptic input of their dendrites increases [174]. Consistent with 
this, an increased neurokinin-1 receptor availability was 
found in temporal lobe epilepsy by positron emission tomo-
graphy study using a substance P receptor ligand [175] sug-
gesting an increased density of substance P receptors in the 
hippocampus. 
Selective peptide agonists of NK-1 receptor have been 
developed. However, these drugs do not possess major 
therapeutic potential [157]. In contrast, NK-1 receptor an-
tagonists are intensively investigated for a variety of neu-
ronal diseases including epilepsy. Consequently, non-peptide 
small molecule antagonists are available including CP-
122,721 [176], GR205171 [177], and MK-869 [178] as 
shown in (Fig. 4). MK-869 (Aprepitant) is used at present as 
an anti-emetic agent [179]. NK-1 receptor antagonists have 
been tested in animal models of epilepsy and were found 
effective. CP-122,721-1, attenuated kainate induced seizure 
activity [180] while GR205171 potentiated the anticonvul-
sant efficacy of sodium channel inhibitors [181]. Thus, re-
search using NK-1 receptor antagonist in epilepsy is ex-
pected to intensify in the future [182]. 
5.6. Cholecystokinin 
Cholecystokinin (CCK) includes peptides with different 
lengths but overlapping sequences cleaved from the same
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propeptide. Longer forms are secreted from I cells of the 
epithelium of the small intestine and act as hormones to in-
crease the amount of digestive enzymes and bile in the duo-
denum [183]. In the brain, the 8 aa CCK is one of the most 
abundant neuropeptides. It is produced in the cerebral cortex, 
the hippocampus, the amygdala, the caudate putamen, the 
hypothalamus, and also in some neurons of additional brain 
regions [184]. In the hippocampus, CCK is present in gran-
ule cells of the dentate gyrus, basket cells, and Schaffer col-
lateral associated and lacunosum-moleculare perforant path 
associated interneurons in the Ammon´s horn [24]. In addi-
tion, seizure-induced appearance of CCK in pyramidal cells 
has also been reported [185]. 
The anti-convulsant action of CCK is controversial. CCK 
inhibited seizures induced by picrotoxin and electroshock in 
rats [186] and in mice [187]. Also, CCK increased vigaba-
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trin-induced anti-convulsant effects [188] and reduced penty-
lenetetrazole-induced kindling [189]. However, pro-
convulsant actions of CCK have also been reported in animal 
models of epilepsy [83]. In addition, CCK produces a well-
documented depolarizing effect on hippocampal neurons that 
leads to the release of glutamate [190, 191]. 
CCK has 2 different receptors CCK1 (previously CCK-
A) and CCK2 (previously CCK-B) receptors, which activate 
phospholipase C via Gq proteins [192]. CCK2 receptor is the 
dominant form in the brain as well as in the hippocampus. 
Selective and potent CCK receptor agonists and antagonists 
have been developed. The first selective CCK2 antagonists 
were modified peptides (Cl-988 and CI-1015). Small mole-
cule CCK2 antagonists (L-365,260, L-369,293, YF-476, RP-
69758, LY-288,513, PD-145,942) and inverse agonist (L-
740,093) have been developed [193, 194], but are typically 
considered in anxiety disorders, panic attack, schizophrenia, 
and alcohol withdrawal, but not for anti-epileptogenic poten-
tial [17, 195-197]. 
5.7. Vasoactive Intestinal Peptide 
Vasoactive intestinal peptide (VIP) is a 28 aa neuropep-
tide expressed in a variety of brain regions [198] including 
all parts of the hippocampal formation. In the hippocampus 
proper, VIP is expressed by interneurons innervating py-
ramidal and granule cell bodies and proximal dendrites (bas-
ket cells) and by interneurons innervating selectively other 
interneurons [199, 200]. Pentylenetetrazol-induced seizures 
resulted in short term decrease in the level of VIP [57, 201]. 
VIP has an overall excitatory action on synaptic transmission 
in the hippocampus [202], in which the cAMP-mediated 
activation of NMDA receptor plays a role [203]. Still, VIP 
was neuroprotective in some models of neurodegeneration 
including neuroinflammation [204] and beta-amyloid-
induced neurodegeneration [205] providing the possible neu-
roprotective role in epileptic sclerosis. 
VIP actions are exerted by G-protein coupled receptors 
VPAC1-R and VPAC2-R [198], which belong to class II of 
G-protein coupled receptors, recognize VIP and also the re-
lated neuropeptide pituitary adenylate cyclase-activating 
polypeptide (PACAP). These receptors were shown to be 
upregulated in hippocampal surgical samples of patients suf-
fering from human temporal lobe epilepsy [206]. Some sub-
type-specific peptide agonists and antagonists for VIP recep-
tors are available. Studies using these peptides suggest that 
VPAC2-R but not VPAC1-R is involved in the VIP en-
hancement of population spikes in the hippocampus [207]. 
Altogether, we can conclude that although the VIP system is 
ideally situated to affect epileptic seizures, data are scarce as 
to their involvement in seizure generation and propagation. 
Development of small molecule drugs acting selectively on 
VIP receptors would be useful in exploring the role of these 
receptors in epilepsy. Thus, while there were a number of 
studies in human subjects with different forms of headache 
where VIP was assessed as a biomarker [208], its utilization 
in epilepsy is not imminent. 
5.8. Ghrelin 
Ghrelin, a 28 aa peptide, was identified as the endoge-
nous ligand of the growth hormone secretagogue receptor 
(GHSR) using reverse pharmacology [209]. Accordingly, 
ghrelin increases the secretion of growth hormone from the 
pituitary. Ghrelin has 2 forms depending whether its serine-3 
residue is acetylated with octanoate, performed by a recently 
identified specific enzyme in about 90% of circulated ghrelin 
[210]. Ghrelin is most abundant in the stomach from which it 
is secreted to the circulation as a hormone. Its serum levels 
increase before meals and decrease after meals as it partici-
pates in the regulation of food intake. Ghrelin is also known 
to be expressed in the hypothalamus while its expression in 
other brain regions is debated [211]. Therefore, it is ques-
tioned sometimes if ghrelin qualifies as a neuropeptide or it 
should be considered only a hormone. Since its neurochemis-
try and anti-epileptic actions are similar to those of other 
neuropeptides, we include the discussion of ghrelin in this 
review. 
The ghrelin receptor gene encodes GHSR1a and 
GHSR1b, of which GHSR1a is the functional ghrelin recep-
tor while GHSR1b might be a negative modulator of 
GHSR1a by dimerization [212]. Activation of GHSR1a acti-
vates the phospholipase C pathway via G 11/Gq11 [213]. 
GHSR is abundant in widespread brain regions including the 
hippocampus [214] although its precise localization within 
the hippocampus is not revealed yet. Similarly, the origin of 
endogenous ghrelin activating these receptors remains to be 
established. A peripheral source is possible as ghrelin can 
penetrate the blood-brain barrier [215]. Despite the uncer-
tainties regarding the neurochemistry of ghrelin, its anti-
epileptic activity has been demonstrated recently [216] 
among other potential therapeutic actions [217]. Ghrelin, 
injected intraperitoneally, reduced the severity of pentyle-
netetrazol-induced seizures [218]. Furthermore, ghrelin at-
tenuated kainic acid-induced neuronal cell death in the 
mouse hippocampus [219] and protected hippocampal neu-
rons in pilocarpine-induced seizures of rats by inhibiting cell 
apoptosis [220]. In turn, another study suggested that only 
des-acylated ghrelin is beneficial in hippocampal seizures 
[221]. Different mechanisms of action were suggested for 
ghrelin action on seizures and its neuroprotective actions. 
Since ghrelin leads to neuropeptide Y and GABA release in 
the hypothalamus, it may have a similar action in the hippo-
campus [214]. Another possibility is that ghrelin induces the 
proliferation of hippocampal neural stem cells [222]. Alter-
natively, it acts as an anti-inflammatory agent, as demon-
strated in the periphery [223]. Recently, another interesting 
hypothesis was suggested based on the finding that the 
GHSR1a receptor has significant basal activity [224] and 
that the GHSR knockout mice had a higher seizure threshold 
than their wild-type littermates [225]: an endogenous agonist 
can have anticonvulsant action by reducing the activity of the 
constitutively active receptor with a combination of inverse 
agonism and desensitization/internalization of the receptor 
[225]. This hypothesis should be tested by newly developed 
inverse agonists of the GHSR1a receptor [226, 227]. 
To utilize actions via the ghrelin receptor, more stable 
analogues were recently developed. BIM-28131, a small 
peptide ghrelin agonist, and BIM-28163, a full-length ghrelin 
analog antagonist were used in some studies on hypotha-
lamic actions of ghrelin [228]. Also, some peptidomimetics 
have been produced including the pseudotripeptide EP01572 
(H-Aib-(D)-Trp-(D)-gTrp-formyl) with increased stability 
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and oral bioavailability [229] even in human [230], and JMV 
1843 [231] shown in (Fig. 5A). 
Subsequently, it was found that the C-terminal of JMV 
1843 is not necessary for ligand binding and can be omitted 
[232], which resulted in JMV 2215 (Fig. 5B). Based on the 
structure of this pseudo-dipeptide, peptidomimetics were 
developed by rigidifying the structure using different hetero-
cycles [233]. Triazoles including JMV 2683 (Fig. 5C) were 
selected as lead compounds. Further structure-activity rela-
tionship studies produced the potent GHSR1a receptor an-
tagonist JMV 2959 (Fig. 5D), which could be used for in 
vivo studies to further establish the mechanism of anti-
convulsant action of ghrelin [233]. In turn, non-peptide ago-
nists have also been developed [234, 235], including NN703 
(Fig. 5E), MK-677 (Fig. 5F), and L-692,429. These agonists 
of the GHSR1a receptor should be used in the future to test 
their anti-convulsant properties. 
5.9. Angiotensins 
The renin-angiotensin system (RAS) has long been 
known as a peripheral regulator of several functions includ-
ing excretion and blood pressure. By now, the components of 
the RAS expressed in the brain are also identified [236]. An-
giotensinogen is cleaved by renin to form the 10 aa angio-
tensin (Ang) I, from which angiotensin converting enzyme 
(ACE) produces the 8 aa AngII. Additional cleavages lead to 
the 7 aa AngIII, and the 6 aa AngIV. Originally described in 
the hypothalamus related to the control of fluid intake [237], 
the RAS has also been identified in other brain regions, too, 
including the cortex and the hippocampus [238-240]. Fur-
thermore, the levels of components of the RAS were 
changed in the hippocampus following pilocarpine treatment 
of rats [241] and audiogenic seizures [242] as well as in hu-
man temporal lobe epilepsy [243]. Initial studies of a re-
search group suggested anti-convulsant actions of Ang pep-
tides against pentylenetetrazol-induced seizures [244] re-
viewed recently [245]. Emerging new data, however, suggest 
a more complex effect of angotensins on seizure activity 
[246]. The anti-convulsant action of AngIV has been con-
firmed in the pilocarpine model of epilepsy [247]. However, 
results using inhibition of ACE and antagonists of AngII 
receptors suggest a pro-convulsant action of AngII in the 
brain. AngII receptor antagonists showed anti-convulsant 
affects in pentylenetetrazol treated rats [248] and both AngII 
receptor antagonists and ACE antagonists attenuated audio-
genic seizures [242]. Moreover, the effects of known anti-
epileptics were potentiated by AngII receptor antagonists in 
electroshock seizures [249, 250] and by ACE inhibitors in 
audiogenic seizures [251]. The pro-convulsive effect of 
AngII could be related to its inhibitory action on GABA re-
lease [252] and its excitatory action on hippocampal pyrami-
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dal cells [240]. The interaction of AngII with other neuro-
modulator systems, particularly adenosine has also been sug-
gested [253]. Given the recent description of distribution of 
nucleosides in human [254, 255], the interaction of AngII 
with nucleosides promises interesting findings in the future. 
The angiotensin II receptor type 1 (AT1) is the most 
widespread receptor recognizing AngII and AngIII. AT2 has 
a similar affinity for angiotensins as AT1 with some prefer-
ence for AngIII while AT4 is activated selectively by 
AngIV. AT1 is coupled to Gq/11 and Gi/o while AT2 to Gi2/3 
[236]. The existence of AT3 became questionable while the 
identity of AT4 is a matter of debate, however, it most likely 
not a G-protein coupled receptor [256]. The candidates for 
AT4 include insulin-regulated aminopeptidase, hepatocyte 
growth factor, and the type 1 tyrosine kinase receptor c-Met 
[257]. All 3 Ang receptors are present in several brain re-
gions. AT4 is the most abundant in the cortex and the hippo-
campus [236]. Elevated mRNA expression was shown for 
AT1 but not for AT2 following audiogenic seizures [242] 
and in temporal lobe epilepsy [243], while no data are avail-
able for AT4. Furthermore, specific AT1 antagonists had 
anti-convulsant properties in animal models of epilepsy [242, 
248-250]. These findings support that the AT1 and possibly 
the AT4 receptors may be involved in the pathophysiology 
of epilepsy. Non-peptide AT1 antagonists (e.g. losartan) and 
ACE inhibitors (e.g. captopril) are available and widely used 
to reduce blood pressure. Their effects in animal models of 
epilepsy suggest the necessity of careful analysis for their 
anti-convulsive actions in human. As for AT4, the identifica-
tion of small but critically important peptide fragments [258] 
and their N- and C-terminal modifications led to the devel-
opment of the selective AT4 agonist N-hexanoic-Tyr-Ile-(6) 
aminohexanoic amide. This molecule was sufficiently blood-
brain barrier permeable to have precognitive effects in Mor-
ris water maze performance [259]. Experiments using selec-
tive AT4 agonists are needed in the future to address their 
anti-convulsive actions. 
5.10. Corticotropin-releasing Hormone and Adrenocorti-
cotropin 
Corticotropin-releasing hormone (CRH), a 41 aa peptide, 
and adrenocorticotropin (ACTH), a 39 aa peptide are pivotal 
elements of the classical stress effector pathway. During 
stress response, CRH synthesized in the paraventricular hy-
pothalamic nucleus leads to the release of ACTH from the 
pituitary, which in turn leads to the secretion of glucocorti-
coids, e.g. cortisol in human and corticosterone in rat, from 
the adrenal gland. In turn, ACTH and glucocorticoids exert a 
negative feed-back to the activity of CRH [260]. More re-
cently, ACTH, CRH and their receptors identified in differ-
ent limbic brain regions were found to be involved in affec-
tive responses [261-263]. Data are available on the changes 
of CRH levels during development and in epilepsy models 
[264]. Interestingly, CRH concentrations in limbic areas are 
the highest during early postnatal development [265]. CRH 
gene expression was up-regulated after pilocarpine induced 
status epilepticus in the strata oriens and pyramidale of CA1 
area and in the stratum pyramidale of CA3 area [266] while 
amygdala-kindled seizures and electroconvulsive shock in-
creased the expression of CRH and CRH-binding protein in 
interneurons of the dentate hilus [267, 268]. A day after sei-
zures, hippocampal areas undergoing neurodegeneration 
exhibited increased CRH immunoreactivity. In fact, net-
works of CRH fibers closely surrounded moribund neurons 
[269]. Elevations in CRH mRNA and immunoreactivity 
were identified not only in the hippocampus but also in the 
bed nucleus of the stria terminalis, the globus pallidus, the 
piriform cortex, and the central nucleus of the amygdala fol-
lowing kainate-induced seizures [270, 271]. However, physi-
cally stressful stimuli, e.g. cold, which activate hypothalamic 
CRH neurons, were not effective in the hippocampus [272]. 
CRH administered into the cerebral ventricles of rats dur-
ing the first postnatal week caused a specific and stereotyped 
behavior sequence: rhythmic chewing and licking (jaw myo-
clonus) followed by 'limbic'-type seizures [273], which re-
sembled kainate and amygdala kindled convulsions [274]. 
Furthermore, death of hippocampal pyramidal cells occurred 
following CRH-induced status epilepticus in infant rats 
[275]. The pro-convulsant actions of corticotropin-releasing 
hormone in the hippocampus of infant rats are consistent 
with the stimulatory activity of CRH on incoming excitatory 
signals reaching pyramidal cells [276]. However, CRH-
produced age-specific seizures correlated with rhythmic 
amygdala discharges while paroxysmal hippocampal and 
cortical discharges developed suggesting that CRH-induced 
electrographic and behavioral seizures may originate in the 
amygdala in infant rats [277]. Reduction of CRH effects, e.g. 
by CRH-saporin, reduced handling-induced seizure suscepti-
bility in a seizure-prone strain [278]. Furthermore, astressin, 
a novel and potent CRH antagonist delayed the onset of 
CRH-induced seizures after infusion into the cerebral ventri-
cles of infant rats [279]. In addition, astressin inhibited ka-
inate-induced seizures and also had neuroprotective features 
[280]. The involvement of CRH in epilepsy was also sup-
ported by genetic studies. Nocturnal frontal lobe epilepsy 
was correlated with a nucleotide variation in the promoter of 
CRH [281], which could result in reduced levels of CRH 
secretion in response to stressful stimuli [282]. 
As opposed to the pro-convulsant activity of CRH, 
ACTH is anti-epileptic. Its efficacy in primary infantile 
spasms is long known [283]. Different protocols are used in 
clinical practice. High-dose, short-duration versus low-dose, 
long-duration ACTH therapies and low-dose alternate-day 
corticotropin therapy could all be effective [284, 285]. 
ACTH clearly increases plasma corticosteroid levels provid-
ing the possibility for indirect actions. However, ACTH 
treatment is superior to steroid (e.g. predonsone) treatment 
for infantile spasms, as assessed by both clinical and EEG 
criteria [286]. There is a substantial amount of evidence 
available that ACTH acts by reducing CRH function in dif-
ferent brain sites, similar to its action in the neuroendocrine 
hypothalamus. ACTH, administered peripherally as well as 
centrally, down-regulated the expression of CRH and CRH-
binding protein in infant rat hippocampus and amygdala 
[287, 288]. ACTH does not control neonatal seizures in-
duced by administration of exogenous CRH [289]. Moreo-
ver, selective blocking of ACTH receptors prevented ACTH-
induced down-regulation of CRH expression [287]. Based on 
these findings, the CRH-excess theory was formulated: the 
many etiologies in early childhood seizures, particularly 
West syndrome, all lead to the production and secretion of 
CRH as part of a central stress response. These effects of 
CRH are restricted to the infancy period because the recep-
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tors for CRH, which mediate its action on neurons, are most 
abundant during this developmental period [290]. ACTH 
administration is known to inhibit production and release of 
CRH via a negative feedback mechanism [291]. However, 
other actions of ACTH, such as a direct potentiation of in-
hibitory interneurons have also been suggested [292]. 
There are 2 CRH receptors, designated as type 1 and 2 
(CRHR1 and CRHR2). These receptors belong to class II of 
G-protein coupled receptors. Both use Gs and Gq/G11 proteins 
to increase adenylate cyclase and phospholipase C activity, 
respectively [293]. Elevated CRHR1 but not CRHR1 expres-
sion was found in post mortem brain obtained from children 
with generalized epilepsy suggesting the role of CRHR1 in 
seizure generation [294]. Furthermore, selective CRH1R but 
not CRH2R antagonists increased the latency and decreased 
the duration of CRH-induced seizures [295]. Thus, CRHR1 
antagonists could be useful in the treatment of early child-
hood seizures. ACTH treatment has some side-effects, in-
cluding potential hypertrophic cardiomyopathy [296]. There-
fore, drugs which block the actions of CRH on its receptors 
may provide a better therapy for early childhood seizures. 
There are some small molecule non-peptide selective an-
tagonists of the CRHR1 available [297] including pexacer-
font (BMS-562,086), antalarmin, and CP-154,526 (Fig. 6). 
These and similar drugs are being tested for depression, al-
coholism, anxiety disorders, etc. 
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Fig. (6). Selective non-peptide antagonists of the CRHR1. 
The receptor of ACTH is the melanocortin-2 receptor 
(MC2R) coupled to Gs proteins to activate adenylate cyclase. 
Other melanocortin receptors whose ligands are melanocyte-
stimulating hormones, do not recognize ACTH [298]. MC2R 
agonists could be useful alternatives of ACTH treatment in 
early childhood seizures, however, such drugs are not avail-
able at present. 
5.11. Thyrotropin-releasing Hormone 
The hypothalamic paraventricular nucleus synthesizes the 
tripeptide thyrotropin-releasing hormone (TRH) to affect 
thyroid hormone secretion from the thyroid gland. In addi-
tion, TRH is also produced in different brain regions includ-
ing the cerebral cortex, the hippocampus, the amygdala, the 
striatum, and the brainstem while experimental models of 
epilepsy induce the largest increase in the hippocampal TRH 
expression [299]. Furthermore, the hippocampal release of 
TRH by seizures has also been reported [300]. In turn, TRH 
inhibits glutamate release but increases GABA release in the 
hippocampus [301, 302], which might be the basis of its anti-
epileptic action. 
TRH was anti-convulsant in experimental models of 
temporal [303, 304] and absence epilepsies [305, 306]. TRH 
is safe in children and effective in some cases of West syn-
drome and Lennox-Gastaut syndrome [307] and in progres-
sive myoclonic epilepsy [308]. TRH was suggested to be 
used if side-effects of ACTH are too disturbing [309]. To 
overcome the problems with bioavailability of TRH, differ-
ent approaches were tested. A TRH was attached to a biode-
gradable polyanhydride copolymer as a sustained-release 
carrier and implanted into the amygdala of kindling rats. The 
anti-convulsant effects provided evidence in support of in 
situ microdisk pharmacotherapy for potential neuropeptide 
delivery in intractable epilepsy [310]. Intranasal delivery of 
3-methyl-histidine TRH was demonstrated to attenuate sei-
zures in amygdala-kindled rats [311]. Furthermore, intrana-
sal application of microdisc nanoparticle containing TRH 
was also effective [312]. 
TRH acts through 2 different G-protein coupled recep-
tors, TRH-R1 and TRH-R2. Both receptors elevate phos-
pholipase C via Gq11. TRH-R1 is the major form in the hypo-
thalamo-pituitary axis while TRH-R2 plays the major role in 
extrahypothalamic brain sites [313]. Although TRH itself 
was shown to have anti-epileptic activity, its short half-life 
and poor penetration through the blood-brain barrier does not 
allow its widespread application [314]. Consequently, a 
number of modified peptide analogues of TRH were synthe-
sized. Although many of these have improved stability, none 
of them is particularly selective for the TRH receptor sub-
types. Still, they represent a tool to affect convulsions, and 
were indeed successfully applied in a variety of experimental 
models and in human [315]. YM-14673 (N alpha-[(S)-4-oxo-
2-azetidinyl]-carbonyl]-L-prolinamide dihydrate) shortened 
afterdischarge duration following kindling [303]. CNK-602A 
(N-[(6-methyl-5-oxo-3-thiomorpholinyl) carbonyl]-L-
histidyl-L-prolinamide) inhibited absence-like seizure and 
tonic convulsion in spontaneously epileptic rats [316, 317]. 
NP-355 (L-pGlu-(1-benzyl)-L-His-L-ProNH(2); Fig. 7) and 
NP-647 (L-pGlu-(2-propyl)-L-His-L-ProNH2) were effec-
tive anti-convulsants in a number of different models of epi-
lepsy [318-320]. Clearly, selective non-peptide molecules 
acting on TRH-R2 would have great anti-epileptic potential 
and their development is awaited. 
5.12. Oxytocin and Vasopressin 
Oxytocin and vasopressin are structurally related 9 aa 
hormones released from the terminals of magnocellular hypo-
thalamic neurons in the pituitary [321]. However, they cannot 
readily penetrate the blood-brain barrier. Therefore, their cen-
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tral actions are probably exerted as neuropeptides synthesized 
in the paraventricular hypothalamic nucleus and possibly other 
brain regions, from which oxytocin- and vasopressin-
containing terminals reach a variety of brain areas [322] in-
cluding the hippocampus [323, 324]. Both oxytocin and vaso-
pressin mRNA expressions are elevated in the paraventricular 
hypothalamic nucleus during seizures [325]. There is an in-
creasing amount of evidence - albeit sometimes contradictory 
- on the effects of oxytocin and vasopressin on seizure activ-
ity. Intraperitoneally injected oxytocin was shown to exacer-
bate pentylenetetrazol-induced seizures in mice [326] while a 
higher concentration of oxytocin was anti-convulsive in the 
same epilepsy model in rats [327]. The enhancement of hippo-
campal inhibitory transmission by oxytocin also supports an 
anti-convulsive action of oxytocin [328, 329]. In contrast, sub-
cutaneously applied vasopressin had pro-convulsive effects 
[330] in agreement with the excitatory potential of this neu-
ropeptide [331, 332]. For concerns on the penetration of oxy-
tocin and vasopressin through the blood-brain-barrier, they 
have also been successfully applied intranasally [333-335]. 
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Fig. (7). The structure of TRH and its analogue NP-355. 
There are 4 mammalian receptors of oxytocin and vaso-
pressin: oxytocin receptor (OTR), and vasopressin receptors 
1a, 1b, and 2 (V1a, V1b, and V2). A significant cross-
reactivity characterizes these ligand-receptor systems. Vaso-
pressin acts on all 4 receptors while oxytocin recognizes 
vasopressin receptors albeit with less affinity than OTR 
[336]. OTR, and possibly vasopressin receptors, too, can 
bind to Gq/11, Gi, and Gs initiating different signaling path-
ways. The predominant neural forms are OTR and V1a, 
which have widespread but complementary expressions in 
the brain including the hippocampus: OTRs are found in the 
CA1 region and the subiculum, while V1 in the dentate 
gyrus, CA2 and CA3 regions [328, 337]. 
There is a considerable amount of evidence that the pro-
convulsive effects of oxytocin and vasopressin are exerted via 
V1a receptor while OTR could be responsible for anti-
convulsive actions [326, 330, 338]. These findings suggest that 
OTR agonists and V1a receptor antagonists could be potential 
drug targets in epilepsy. The pharmacology of oxytocin and 
vasopressin receptors is well elaborated [339]. There are selec-
tive non-peptide OTR agonists, such as compound 39 (Fig. 8A) 
and WAY-267,464 (Fig. 8B) and selective V1a receptor antago-
nists including the orally active relcovaptan (Fig. 8C) available 
[340-342]. These drugs represent important tools to further de-
fine the involvement of oxytocin and vasopressin receptors in 
epilepsy by means of their usage in animal experimentation. 
6. COMPARISON OF NEUROPEPTIDE SYSTEMS 
REGARDING THEIR ROLE IN EPILEPSY AND 
THEIR THERAPEUTIC POTENTIAL 
Neuropeptide systems possess inherent similarities be-
cause of their similar character and neurochemical nature. 
On the other hand, their modulatory actions also differ from 
each other. They have different distributions in the brain and 
also within specific brain regions, e.g. the hippocampus, 
which was best studied for their importance in epilepsy. 
Neuropeptides with well-established profile in the hippo-
campus are studied for their role in temporal lobe epilepsies. 
Obviously, such a role does not exclude their involvement in 
other types of epilepsies. Still, the focus of research for pep-
tides such as CRH and ACTH, where the latter is used for 
the treatment of early childhood epilepsies is understandably 
different. The role of none of the neuropeptides is so firmly 
established that some types of epilepsies should be excluded 
from their investigations. Some neuropeptides, e.g. NPY 
[28], dynorphin [139], TRH [305, 306] are known to be in-
volved in absence epilepsy, too. However, many other neu-
ropeptides have not been thoroughly investigated in animal 
models of absence epilepsies. 
The neuropeptides described in this chapter are all impli-
cated to some degree with seizures (Table 1). However, the 
strength of evidence supporting their involvement is differ-
ent. Most of the peptides demonstrate altered levels during or 
after seizures, which is, however, only indicative for their 
role in seizure, and an indirect evidence at best. The peptides 
discussed were all tested for their effects in convulsion, too. 
Most of the neuropeptides have anti-convulsive actions. 
However, some of them, such as enkephalin, substance P, 
CCK, AngII, CRH, and vasopressin were generally pro-
convulsive. For peptides, the role of which in seizure genera-
tion or maintenance is best established, pharmacological 
antagonism or transgenic studies supported the results of 
peptide injections. E.g. mice lacking somatostatin receptors 
[46], functional NPY [64] or galanin gene or receptor [89] 
were prone to seizures and showed increased sensitivity for 
convulsive agents. On the other hand, for CCK and VIP, the 
evidence supporting their role in any seizure activity is rela-
tively weak. Even for peptides with firmly established anti- 
or pro-convulsive effect, the mechanisms behind the actions 
remain obscure. The exact localization of their receptors 
(excitatory or inhibitory neurons, cell body, axon terminal, 
proximal, or distal dendrite, etc.), their signal transduction 
and electrophysiological analysis has to be clarified for many 
neuropeptides and cell types in the future. Furthermore, these 
properties may change in the course of seizures. Neuropep-
tides are released during overstimulation and their subse-
quent absence in the tissue may contribute to the mainte-
nance of seizures, an event, which is incompletely under-
stood. Still, it is critically important for the treatment of epi-
lepsy if a neuropeptide receptor can interrupt this mainte-
nance phase as shown for galanin and dynorphin as opposed 
to only influences the initiation of seizures [2, 343]. 
Another critically important issue using neuropeptide 
systems in epilepsy therapy is the advancement of their 
pharmacology. This means developing drugs acting on their 
receptors as their synthesizing and degrading enzymes are 
not known yet or are not sufficiently specific to be exploited, 
except for angiotensin (ACE blockers). It is particularly chal-
lenging to produce stable, small molecule drugs acting on 
neuropeptide receptors that cross the blood-brain barrier. 
Such pharmacology is the most progressed for opioid pep-
tides, angiotensin II, agonists and antagonists of which are 
used in clinical practice but were still not suitable for 
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Fig. (8). Non-peptide molecules acting selectively on oxytocin and vasopressin receptor subtypes. 
 
Table 1. The Comparison of the State of Research Regarding the Receptors of Neuropeptides Potentially Involved in Seizures and 
Selective Drugs Acting on the Receptor Subtypes that are Potentially Involved in Epilepsy 
Neuropeptid 
Size 
(aa) 
Receptors 
Receptor Types Involved 
in Seizures 
Feature of Potentially 
Anti-convulsive Drugs 
Selective, Non-peptide, Potentially 
Anti-convulsive Compounds 
sst2 agonists L779.976; L-054,522 
sst3 agonists L-796,778 
Somatostatin 14 sst1-sst5 sst2, sst3, sst4 
sst4 agonists L-803,087; NNC 26-9100 
Y1 antagonists BIBP-3226, BIBO-3226 NPY 36 Y1, 2, 4, 5 Y1, Y2, Y5 
Y2, Y5 agonists  
Galanin 29 GalR1, 2, 3 GalR1, GalR2 GalR1/2 positive allosteric 
modulators 
Galmic, Galnon, CYM2503 
MOR antagonists Cyprodime; beta-Funaltrexamine Enkephalin 5 MOR (μ) 
DOR () 
MOR, DOR 
DOR antagonists Naltrindol, Naltriben 
Dynorphin 13 KOR () KOR KOR agonists Butophanol; Cyclazocine; U-50488 
Substance P 11 NK-1 NK-1 NK-1 antagonists CP-122,721; GR205171; MK-869 
CCK2 antagonists L-365,260; YF-476; RP-69758 CCK 8 CCK1, 2 CCK2 ? 
CCK2 inverse agonists L-740,093 
VIP 28 VPAC1,2-R VPAC2-R ?   
Ghrelin 28 GHSR1a GHSR1a GHSR1a agonists NN703; MK-677; L-692,429 
AT1 antagonists Losartan AngII 8 AT1, 2 AT1 
ACE inhibitors Captopril 
AngIV 6 AT4 AT4 AT4 agonists  
CRH 41 CRHR1, 2 CRHR1 CRHR1 antagonists Pexacerfont; Antalarmin; CP-154,526 
ACTH 39 MC2R MC2R MC2R agonists  
TRH 3 TRH-R1, 2 TRH-R2 TRH-R2 agonists  
Oxytocin 9 OTR OTR OTR agonists Compound 39, WAY-267,464 
Vasopressin 9 OTR, V1a 
V1b, V2 
V1a V1a antagonists Relcovaptan 
 
epilepsy. In fact, there are no drugs acting on neuropeptide 
receptors used for the treatment of epilepsy except for ACTH 
and to some degree TRH for early childhood seizures. Re-
cent progress is, however promising for galanin, NPY, ghre-
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lin, and to some degree somatostatin and substance P (Table 
1). A potential approach to tackle the difficulty of develop-
ing small molecules that bind the large binding sites of pep-
tides is using allosteric modulators, which was most success-
ful for galanin receptors [102]. In addition, solutions are 
tested that can possibly circumvent the problem of develop-
ing orally available drugs. Tools for subcutaneous delivery 
are becoming more convenient. The stability of peptides can 
be enhanced by reducing their degradation after better under-
standing of this process. Furthermore, attempts are promising 
for using existent transport mechanisms to support the pene-
tration of therapeutic peptides through the blood-brain bar-
rier [17, 344]. Another possible solution is gene transfer de-
livery of neuropeptides, e.g. by using viral tools [20, 22]. 
These approaches are most advanced for NPY [66]. 
7. CONCLUSION 
We demonstrated here that epileptic activity of all forms of 
epilepsy can be modulated by activating and inhibiting differ-
ent neuropeptide receptors that shifts the excitatory/inhibitory 
balance out of hyperexcitability range. Thus, neuropeptide 
receptors represent very promising novel targets for drug de-
velopment in general because of the potentially low side-
effects and because they possess the pharmacologically least 
exploited G-protein receptors. In particular, the endogenous 
functions of neuropeptides, their sustained and specific influ-
ence on neuronal excitation and gene transcription make them 
appealing for the development of anti-epileptic drugs. How-
ever, the difficulties for their therapeutic applications are also 
significant, as proteases quickly degrade peptides, and the 
large binding sites make is difficult to develop small agonists 
and antagonist of neuropeptide receptors. In fact, the majority 
of the currently available drugs listed in the manuscript are 
suitable only for basic research with limited therapeutic poten-
tial. However, recent progress in the field makes us to believe 
that neuropeptide systems will be utilized clinically for the 
treatment of epilepsy in the near future via developing pepti-
domimetics or other non-peptide agonists, antagonists, allos-
teric regulators, etc., and even gene transfer methods. In par-
ticular, recent progress with neuropeptide Y and ghrelin recep-
tor drugs are promising. Our conclusive message is that inves-
tigation of neuropeptides in epilepsy must be boosted up to get 
more targets for drug development. 
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ABBREVIATIONS 
aa = Amino acid 
ACE = Angiotensin converting enzyme 
ACTH = Adrenocorticotropin 
Ang = Angiotensin 
AT1 = Angiotensin II receptor type 1 
CCK = Cholecystokinin 
CCK1 = Cholecystokinin 1 receptor 
CRH = Corticotropin-releasing hormone 
DOR = Delta-opioid receptor 
GalR = Galanin receptor 
GHSR = Growth hormone secretagogue receptor 
KOR = Kappa-opioid receptor 
MC2R = Melanocortin-2 receptor 
MOR = mu-opioid receptor 
NK-1 = Neurokinin-1 receptor 
NPY = Neuropeptide Y 
OTR = Oxytocin receptor 
PACAP = Pituitary adenylate cyclase-activating 
polypeptide 
RAS = Renin-angiotensin system 
sst = Somatostatin receptors 
TRH = Thyrotropin-releasing hormone 
V = Vasopressin receptor 
VIP = Vasoactive intestinal peptide 
Y = Neuropeptide Y receptor 
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